blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3113630

EP3113630 - PROBIOTIC FORMULATIONS AND METHODS FOR USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.10.2020
Database last updated on 14.11.2024
FormerThe patent has been granted
Status updated on  08.11.2019
FormerGrant of patent is intended
Status updated on  04.07.2019
FormerExamination is in progress
Status updated on  01.05.2019
FormerGrant of patent is intended
Status updated on  08.01.2019
FormerExamination is in progress
Status updated on  28.05.2018
FormerGrant of patent is intended
Status updated on  07.01.2018
FormerExamination is in progress
Status updated on  30.06.2017
FormerRequest for examination was made
Status updated on  09.12.2016
FormerThe international publication has been made
Status updated on  16.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
The Research Institute at Nationwide Children's Hospital
700 Children's Drive
Columbus, Ohio 43205 / US
For all designated states
Ohio State Innovation Foundation
1524 North High Street
Columbus, OH 43201 / US
[2017/02]
Inventor(s)01 / GOODMAN, Steven D.
c/o Research Institute at
Nationwide Children's Hospital
700 Children's Drive
Columbus, Ohio 43205 / US
02 / BAKALETZ, Lauren O.
c/o Research Institute at
Nationwide Children's Hospital
700 Children's Drive
Columbus, Ohio 43205 / US
03 / BESNER, Gail
c/o Research Institute at
Nationwide Children's Hospital
700 Children's Drive
Columbus, Ohio 43205 / US
04 / BAILEY, Michael
c/o Ohio State Innovation Foundation
1524 North High Street
Columbus, Ohio 43201 / US
 [2017/02]
Representative(s)Tomkins & Co
5 Dartmouth Road
Dublin 6 / IE
[2017/02]
Application number, filing date15710693.105.03.2015
[2017/02]
WO2015US19059
Priority number, dateUS201461949058P06.03.2014         Original published format: US 201461949058 P
[2017/02]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015134808
Date:11.09.2015
Language:EN
[2015/36]
Type: A2 Application without search report 
No.:EP3113630
Date:11.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 11.09.2015 takes the place of the publication of the European patent application.
[2017/02]
Type: B1 Patent specification 
No.:EP3113630
Date:11.12.2019
Language:EN
[2019/50]
Search report(s)International search report - published on:EP28.01.2016
ClassificationIPC:A23L33/10, A23L33/17
[2017/02]
CPC:
A23L33/135 (EP,US); A61K35/747 (US); A23L33/195 (EP,US);
A61K9/1611 (US); A61K9/1647 (US); A61K9/1652 (US);
A61K9/1658 (US); A61P1/00 (EP); A61P1/02 (EP);
A61P1/04 (EP); A61P11/02 (EP); A61P15/00 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P25/00 (EP);
A61P31/04 (EP); A61P37/02 (EP); A61P43/00 (EP);
A23V2002/00 (EP,US); A23V2200/3202 (EP,US); A23V2200/3204 (EP,US) (-)
C-Set:
A23V2002/00, A23V2200/3202, A23V2200/3204 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/02]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:PROBIOTISCHE FORMULIERUNGEN UND VERFAHREN ZUR VERWENDUNG[2017/02]
English:PROBIOTIC FORMULATIONS AND METHODS FOR USE[2017/02]
French:PRÉPARATIONS PROBIOTIQUES ET MÉTHODES D'UTILISATION ASSOCIÉES[2017/02]
Entry into regional phase21.09.2016National basic fee paid 
21.09.2016Designation fee(s) paid 
21.09.2016Examination fee paid 
Examination procedure21.09.2016Examination requested  [2017/02]
21.09.2016Date on which the examining division has become responsible
10.04.2017Amendment by applicant (claims and/or description)
03.07.2017Despatch of a communication from the examining division (Time limit: M04)
24.08.2017Reply to a communication from the examining division
08.01.2018Communication of intention to grant the patent
18.05.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.05.2018Fee for grant paid
18.05.2018Fee for publishing/printing paid
03.07.2018Despatch of a communication from the examining division (Time limit: M04)
30.10.2018Reply to a communication from the examining division
09.01.2019Communication of intention to grant the patent
26.04.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.07.2019Communication of intention to grant the patent
30.10.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19154908.8  / EP3536168
Opposition(s)14.09.2020No opposition filed within time limit [2020/47]
Fees paidRenewal fee
27.03.2017Renewal fee patent year 03
13.03.2018Renewal fee patent year 04
13.03.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.03.2015
AL11.12.2019
AT11.12.2019
CY11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
MK11.12.2019
MT11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
TR11.12.2019
LU05.03.2020
BG11.03.2020
NO11.03.2020
GR12.03.2020
BE31.03.2020
IS11.04.2020
PT06.05.2020
[2022/32]
Former [2022/27]HU05.03.2015
AL11.12.2019
AT11.12.2019
CY11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
MT11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
TR11.12.2019
LU05.03.2020
BG11.03.2020
NO11.03.2020
GR12.03.2020
BE31.03.2020
IS11.04.2020
PT06.05.2020
Former [2021/10]AL11.12.2019
AT11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
IT11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
NL11.12.2019
PL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
LU05.03.2020
BG11.03.2020
NO11.03.2020
GR12.03.2020
BE31.03.2020
IS11.04.2020
PT06.05.2020
Former [2021/04]AL11.12.2019
AT11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
LU05.03.2020
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/50]AL11.12.2019
AT11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
MC11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SI11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/47]AL11.12.2019
CZ11.12.2019
DK11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/40]AL11.12.2019
CZ11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
IS11.04.2020
PT06.05.2020
Former [2020/37]AL11.12.2019
CZ11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
SK11.12.2019
SM11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
PT06.05.2020
Former [2020/36]AL11.12.2019
CZ11.12.2019
EE11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
PT06.05.2020
Former [2020/35]AL11.12.2019
CZ11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RO11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/34]AL11.12.2019
ES11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/32]AL11.12.2019
FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
NL11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/25]FI11.12.2019
HR11.12.2019
LT11.12.2019
LV11.12.2019
RS11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/23]FI11.12.2019
LT11.12.2019
LV11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
GR12.03.2020
Former [2020/22]FI11.12.2019
LT11.12.2019
SE11.12.2019
BG11.03.2020
NO11.03.2020
Former [2020/21]NO11.03.2020
Cited inInternational search[XAYI]US2011008493  (ZOREA YOHAI [IL]) [X] 1-3,6,24,25,41,46,50 * paragraphs [0008] , [0011] , [0015] , [0019] , [0020] * * examples 1,2 * [A] 4,26 [Y] 15 [I] 42-45,48,49,51;
 [XAYI]US2012247993  (PALAZZI KEN [AU], et al) [X] 1,6,24,41,46 * paragraphs [0008] - [0011] * * paragraphs [0018] - [0022] * * paragraphs [0026] - [0029] * * paragraph [0054] * * examples 1,2; claims 1,2,6,10 * [A] 4,26 [Y] 15[I] 42-45,47-51;
 [XAYI]DE202013103204U  (PHARMACEUTICAL BIOTECHNOLOGY S R O [CZ]) [X] 1-3,24,25,41,46,47,50 * paragraphs [0017] , [0018] * * paragraphs [0023] - [0025] * * examples 1-5; claims 1-3,5,7-9 * [A] 4,26 [Y] 15 [I] 42-45,48,49,51
by applicantUS4683195
 US6638369
 EP2450062
 US8815276
    - NATARO; KAPER, "Diarrheagenic Escherichia Coli", CLIN MICROBIOL REV., (1998), vol. 11, pages 142 - 201
    - BORENSHTEIN, M. ET AL., "Utility of the Citrobacter rodentium Infection Model in Laboratory Mice", CURR OPIN GASTROENTEROL, (2008), vol. 24, pages 32 - 7
    - LUPERCHIO; SCHAUER, "Molecular Pathogenesis of Citrobacter rodentium and Transmissible Murine Colonic Hyperplasia", MICROBES INFECT, (2001), vol. 3, pages 333 - 40
    - MUNDY, T. T. ET AL., "Citrobacter rodentium of Mice and Man", CELL MICROBIOL, (2005), vol. 7, pages 1697 - 706
    - LUPERCHIO; SCHAUER, "Molecular Pathogenesis of Citrobacter rodentium and Transmissible Murine Colonic Hyperplasia", MICROBES INFECT., (2001), vol. 3, pages 333 - 40
    - WLODARSKA, B. ET AL., "Antibiotic Treatment Alters the Colonic Mucus Layer and Predisposes the Host to Exacerbated Citrobacter rodentium-Induced Colitis", INFECT IMMUN, (2011), vol. 79, pages 1536 - 45
    - LUPP, M. L. ET AL., "Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae", CELL HOST MICROBE, (2007), vol. 2, pages 119 - 29
    - WLODARSKA, B. ET AL., "Antibiotic Treatment Alters the Colonic Mucus Layer and Predisposes the Host to Exacerbated Citrobacter rodentium-Induced Colitis", INFECT IMMUN., (2011), vol. 79, pages 1536 - 45
    - MORGAN ET AL., "Dysfunction of the Intestinal Microbiome in Inflammatory Bowel Disease and Treatment", GENOME BIOL., (2012), vol. 13, page R79
    - CARROLL ET AL., "Alterations in Composition and Diversity of the Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome", NEUROGASTROENTEROL MOTIL., (2012), vol. 24, pages 521 - 30
    - CHASSARD, M. ET AL., "Functional Dysbiosis within the Gut Microbiota of Patients with Constipated-Irritable Bowel Syndrome", ALIMENT PHARMACOL THER., (2012), vol. 35, pages 828 - 38
    - HEMARAJATA; VERSALOVIC, "Effects of Probiotics on Gut Microbiota: Mechanisms of Intestinal Immunomodulation and Neuromodulation", THERAP ADV GASTROENTEROL, (2013), vol. 6, pages 39 - 51
    - LIN ET AL., "Probiotic Lactobacillus reuteri Suppress Proinflammatory Cytokines Via C-Jun", INFLAMM BOWEL DIS., (2008), vol. 14, pages 1068 - 83
    - JONES; VERSALOVIC, "Probiotic Lactobacillus reuteri Biofilms Produce Antimicrobial and Anti-Inflammatory Factors", BMC MICROBIOL, (2009), vol. 9, page 35
    - LIN ET AL., "Probiotic Lactobacillus Reuteri Suppress Proinflammatory Cytokines Via C-Jun", INFLAMM BOWEL DIS., (2008), vol. 14, pages 1068 - 83
    - EATON, A. ET AL., "Probiotic Lactobacillus reuteri Ameliorates Disease Due to Enterohemorrhagic Escherichia coli in Germfree Mice", INFECT IMMUN., (2011), vol. 79, pages 185 - 91
    - SCHREIBER ET AL., "Lactobacillus reuteri Prevents Colitis by Reducing P-Selectin-Associated Leukocyte- and Platelet-Endothelial Cell Interactions", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, (2009), vol. 296, pages G534 - 42
    - MACKOS ET AL., "Probiotic Lactobacillus reuteri Attenuates the Stressor-Enhanced Severity of Citrobacter rodentium Infection", INFECT IMMUN, (2013), vol. 81, pages 3253 - 63
    - MAUNDER ET AL., "The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence", CURR MOL MED, (2008), vol. 8, pages 247 - 252
    - WALER ET AL., "The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders", AM J GASTROENTEROL, (2008), vol. 103, pages 1989 - 1997
    - GULOKSUZ ET AL., "Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability", PLOS ONE, (2013), vol. 8, no. 3, page E6043
    - Methods in Enzymology, ACADEMIC PRESS, INC.
    - LAINE ET AL., EUR. J. BIOCHEM., (1980), vol. 103, no. 3, pages 447 - 481
    - Current Protocols in Molecular Biology, (1987), vol. 30
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY
    - MACKOS ET AL., INFECTION AND IMMUNITY, (2013), vol. 81, no. 9, pages 3253 - 3262
    - KOO; WANKAT, KOREAN BIOCHEM. J., (1988), vol. 21, no. 1
    - BEER ET AL., "Poly (Lactic-Glycolic) Acid Copolymer Encapsulation of Recombinant Adenovirus Reduces Immunogenicity in Vivo", GENE THER, (1998), vol. 5, pages 740 - 6
    - KUMARI ET AL., "Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems", COLLOIDS SURF B BIOINTERFACES, (2010), vol. 75, pages 1 - 18
    - MACKOS ET AL., "Probiotic Lactobacillus reuteri Attenuates the Stressor-Enhanced Severity of Citrobacter Rodentium Infection", INFECT IMMUN, (2013), vol. 81, pages 3253 - 63
    - ABEE; KUIPERS, "Understanding Microbial Behavior within and Outside the Host to Improve Food Functionality and Safety", CURR OPIN BIOTECHNOL, (2011), vol. 22, pages 133 - 5
    - FLEMMING; WINGENDER, "The Biofilm Matrix", NAT REV MICROBIOL, (2010), vol. 8, pages 623 - 33
    - GOODMAN ET AL., "Biofilms Can Be Dispersed by Focusing the Immune System on a Common Family of Bacterial Nucleoid-Associated Proteins", MUCOSAL IMMUNOL, (2011), vol. 4, pages 625 - 37
    - F. CHELLAT ET AL., "In Vitro and in Vivo Biocompatibility of Chitosan-Xanthan Polyionic Complex", J BIOMED MATER RES., (2000), vol. 51, pages 107 - 16
    - D. COSTA ET AL., "Swelling Behavior of a New Biocompatible Plasmid DNA Hydrogel", COLLOIDS SURF B BIOINTERFACES, (2012), vol. 92, pages 106 - 12
    - KAUFFMAN ET AL., "Synthesis and Characterization of Acetalated Dextran Polymer and Microparticles with Ethanol as a Degradation Product", ACS APPL MATER INTERFACES, (2012), vol. 4, pages 4149 - 55
    - SINHA ET AL., "Poly-Epsilon-Caprolactone Microspheres and Nanospheres: An Overview", INT J PHARM, (2004), vol. 278, pages 1 - 23
    - TOPUZ; O. OKAY, "Formation of Hydrogels by Simultaneous Denaturation and CrossLinking of DNA", BIOMACROMOLECULES, (2009), vol. 10, pages 2652 - 61
    - FREDENBERG ET AL., "The Mechanisms of Drug Release in Poly(Lactic-Co-Glycolic Acid)-Based Drug Delivery Systems--a Review", INT J PHARM, (2011), vol. 415, pages 34 - 52
    - MESSOUDI ET AL., "Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers", BR J NUTRI, (2011), vol. 105, pages 755 - 764
    - T. ABEE; O. P. KUIPERS, "Understanding Microbial Behavior within and Outside the Host to Improve Food Functionality and Safety", CURR OPIN BIOTECHNOL, (2011), vol. 22, pages 133 - 5
    - L. T. AXELSSON ET AL., "Production of a Broad Spectrum Antimicrobial Substance by Lactobacillus Reuteri", MICROBIAL ECOLOGY IN HEALTH AND DISEASE, (1989), page 2
    - M. T. BAILEY ET AL., "Stressor Exposure Disrupts Commensal Microbial Populations in the Intestines and Leads to Increased Colonization by Citrobacter Rodentium", INFECT IMMUN, (2010), vol. 78, pages 1509 - 19
    - S. J. BEER ET AL., "Poly (Lactic-Glycolic) Acid Copolymer Encapsulation of Recombinant Adenovirus Reduces Immunogenicity in Vivo", GENE THER, (1998), vol. 5, pages 740 - 6
    - X. M. BEN ET AL., "Low Level of Galacto-Oligosaccharide in Infant Formula Stimulates Growth of Intestinal Bifidobacteria and Lactobacilli", WORLD J GASTROENTEROL, (2008), vol. 14, pages 6564 - 8
    - "Global, Regional, and National Causes of Child Mortality in 2008: A Systematic Analysis", R. E. BLACK ET AL., Lancet, W. H. O. CHILD HEALTH EPIDEMIOLOGY REFERENCE GROUP OF, AND UNICEF, (2010), vol. 375, pages 1969 - 87
    - D. BORENSHTEIN ET AL., "Utility of the Citrobacter Rodentium Infection Model in Laboratory Mice", CURR OPIN GASTROENTEROL, (2008), vol. 24, pages 32 - 7
    - C. P. BRAEGGER; T. T. MACDONALD, "Immune Mechanisms in Chronic Inflammatory Bowel Disease", ANN ALLERGY, (1994), vol. 72, pages 135 - 41
    - M. CARROLL ET AL., "lterations in Composition and Diversity of the Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome", NEUROGASTROENTEROL MOTIL, (2012), vol. 24, pages 521 - 30
    - C. CHASSARD, M. ET AL., "Functional Dysbiosis within the Gut Microbiota of Patients with Constipated-Irritable Bowel Syndrome", ALIMENT PHARMACOL THER, (2012), vol. 35, pages 828 - 38
    - F. CHELLAT, M. ET AL., "In Vitro and in Vivo Biocompatibility of Chitosan-Xanthan Polyionic Complex", J BIOMED MATER RES, (2000), vol. 51, pages 107 - 16
    - D. COSTA, J. ET AL., "Swelling Behavior of a New Biocompatible Plasmid DNA Hydrogel", COLLOIDS SURF B BIOINTERFACES, (2012), vol. 92, pages 106 - 12
    - J. C. DE MAN, M. ET AL., "A Medium for the Cultivation of Lactobacilli", J APPLIED BACTERIOLOGY, (1960), vol. 23, pages 130 - 35
    - K. A. EATON, A. ET AL., "Probiotic Lactobacillus Reuteri Ameliorates Disease Due to Enterohemorrhagic Escherichia Coli in Germfree Mice", INFECT IMMUN, (2011), vol. 79, pages 185 - 91
    - L. ECKMANN, "Animal Models of Inflammatory Bowel Disease: Lessons from Enteric Infections", ANN N Y ACAD SCI, (2006), vol. 1072, pages 28 - 38 8
    - H. C. FLEMMING; J. WINGENDER, "The Biofilm Matrix", NAT REV MICROBIOL, (2010), vol. 8, pages 623 - 33
    - S. FREDENBERG, M. ET AL., "The Mechanisms of Drug Release in Poly(Lactic-Co-Glycolic Acid)-Based Drug Delivery Systems--a Review", INT J PHARM, (2011), vol. 415, pages 34 - 52
    - M. O. FREIRE, P. ET AL., "Development of an Animal Model for Aggregatibacter Actinomycetemcomitans Biofilm-Mediated Oral Osteolytic Infection: A Preliminary Study", J PERIODONTOL, (2011), vol. 82, pages 778 - 89
    - S. D. GOODMAN, K. P. ET AL., "Biofilms Can Be Dispersed by Focusing the Immune System on a Common Family of Bacterial Nucleoid-Associated Proteins", MUCOSAL IMMUNOL, (2011), vol. 4, pages 625 - 37
    - J. E. GUSTAVE ET AL., "Targeting Bacterial Integration Host Factor to Disrupt Biofilms Associated with Cystic Fibrosis", J CYST FIBROS, (2013), vol. 12, pages 384 - 9
    - P. HEMARAJATA; J. VERSALOVIC, "Effects ofProbiotics on Gut Microbiota: Mechanisms of Intestinal Immunomodulation and Neuromodulation", THERAP ADV GASTROENTEROL, (2013), vol. 6, pages 39 - 51
    - L. M. HIGGINS ET AL., "Citrobacter Rodentium Infection in Mice Elicits a Mucosal Thl Cytokine Response and Lesions Similar to Those in Murine Inflammatory Bowel Disease", INFECT IMMUN, (1999), vol. 67, pages 3031 - 9
    - F. ITO, H. ET AL., "Factors Affecting the Loading Efficiency of Water-Soluble Drugs in Plga Microspheres", COLLOIDS SURF B BIOINTERFACES, (2008), vol. 61, pages 25 - 9
    - S. E. JONES; J. VERSALOVIC, "Probiotic Lactobacillus Reuteri Biofilms Produce Antimicrobial and Anti-Inflammatory Factors", BMC MICROBIOL, (2009), vol. 9, page 35
    - S. S. JUSTICE, B. ET AL., "Aberrant Community Architecture and Attenuated Persistence of Uropathogenic Escherichia Coli in the Absence of Individual Ihf Subunits", PLOS ONE, (2012), vol. 7, page E48349
    - K. J. KAUFFMAN, C. ET AL., "Synthesis and Characterization of Acetalated Dextran Polymer and Microparticles with Ethanol as a Degradation Product", ACS APPL MATER INTERFACES, (2012), vol. 4, pages 4149 - 55
    - A. KUMARI ET AL., "Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems", COLLOIDS SURF B BIOINTERFACES, (2010), vol. 75, pages 1 - 18
    - S. L. LEBEIS ET AL., "Protective and Destructive Innate Immune Responses to Enteropathogenic Escherichia Coli and Related a/E Pathogens", FUTURE MICROBIOL, (2008), vol. 3, pages 315 - 28
    - Y. P. LIN ET AL., "Probiotic Lactobacillus Reuteri Suppress Proinflammatory Cytokines Via C-Jun", INFLAMM BOWEL DIS, (2008), vol. 14, pages 1068 - 83
    - S. A. LUPERCHIO; D. B. SCHAUER, "Molecular Pathogenesis of Citrobacter Rodentium and Transmissible Murine Colonic Hyperplasia", MICROBES INFECT, (2001), vol. 3, pages 333 - 40
    - C. LUPP; M. L. ROBERTSON ET AL., "Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae", CELL HOST MICROBE, (2007), vol. 2, pages 119 - 29
    - A. R. MACKOS ET AL., "Probiotic Lactobacillus Reuteri Attenuates the Stressor-Enhanced Severity ofCitrobacter Rodentium Infection", INFECT IMMUN, (2013), vol. 81, pages 3253 - 63
    - X. C. MORGAN ET AL., "Dysfunction of the Intestinal Microbiome in Inflammatory Bowel Disease and Treatment", GENOME BIOL, (2012), vol. 13, page R79
    - R. MUNDY ET AL., "Citrobacter Rodentium of Mice and Man", CELL MICROBIOL, (2005), vol. 7, pages 1697 - 706
    - J. P. NATARO; J. B. KAPER, "Diarrheagenic Escherichia Coli", CLIN MICROBIOL REV, (1998), vol. 11, pages 142 - 201
    - L. A. NOVOTNY ET AL., "Structural Stability of Burkholderia Cenocepacia Biofilms Is Reliant on Edna Structure and Presence of a Bacterial Nucleic Acid Binding Protein", PLOS ONE, (2013), vol. 8, page E67629
    - G. A. PREIDIS ET AL., "Probiotics Stimulate Enterocyte Migration and Microbial Diversity in the Neonatal Mouse Intestine", FASEB J, (2012), vol. 26, pages 1960 - 9
    - L. A. SARMIENTO-RUBIANO ET AL., "Dietary Supplementation with Sorbitol Results in Selective Enrichment of Lactobacilli in Rat Intestine", RES MICROBIOL, (2007), vol. 158, pages 694 - 701
    - O. SCHREIBER ET AL., "Lactobacillus Reuteri Prevents Colitis by Reducing P-Selectin-Associated Leukocyte- and Platelet-Endothelial Cell Interactions", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, (2009), vol. 296, pages G534 - 42
    - V. R. SINHA ET AL., "Poly-Epsilon-Caprolactone Microspheres and Nanospheres: An Overview", INT J PHARM, (2004), vol. 278, pages 1 - 23
    - N. TAKEMURA ET AL., "Inulin Prolongs Survival of Intragastrically Administered Lactobacillus Plantarum No. 14 in the Gut of Mice Fed a High-Fat Diet", J NUTR, (2010), vol. 140, pages 1963 - 9
    - F. TOPUZ; 0. OKAY, "Formation of Hydrogels by Simultaneous Denaturation and CrossLinking of DNA", BIOMACROMOLECULES, (2009), vol. 10, pages 2652 - 61
    - M. WLODARSKA ET AL., "Antibiotic Treatment Alters the Colonic Mucus Layer and Predisposes the Host to Exacerbated Citrobacter Rodentium-Induced Colitis", INFECT IMMUN, (2011), vol. 79, pages 1536 - 45
    - Q. XIA ET AL., "Quantitative Analysis of Intestinal Bacterial Populations from Term Infants Fed Formula Supplemented with Fructo-Oligosaccharides", J PEDIATR GASTROENTEROL NUTR, (2012), vol. 55, pages 314 - 20
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.